Nuclera has announced the launched of a nanodisc panel focused on supporting G-Protein Coupled Receptors (GPCR) research and streamlining membrane protein production. 

Building on the eProtein Discovery membrane protein workflow capabilities, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of challenging therapeutic targets, GPCRs, producing active proteins in 48 hours.

The company says the nanodisc panel minimises variability associated with traditional approaches to membrane protein production, targeting the specific charge, fluidity and/or cholesterol requirements for GPCR activity and yield. 

While a third of FDA-approved drugs act on GPCRs, obtaining purified, stable, functional GPCRs remains a critical bottleneck in pharmacology and drug discovery. Traditionally, cell-based detergent micelles are used to solubilise membrane proteins but often lead to proteins adopting non-native conformations.  

Nanodiscs provide a soluble membrane bilayer, allowing the study of membrane proteins and their interactions under native-like conditions. This is said to better maintain structural integrity and in vivo functionality compared to detergent-based approaches. 

“Since releasing our membrane protein workflow in 2025, we have identified a huge potential in the market to support GPCR protein scientists,” said Dr Audrey Dubourg, Product Manager at Nuclera. 

“Our eProtein Discovery nanodisc panel empowers researchers to explore physiologically relevant environments validated for solubility, insertion and stabilisation of membrane proteins.  

“Compared to traditional approaches, these are capable of increasing protein yield whilst maintaining functionality, creating a fast-track route to purified, active GPCRs.” 

“The release of our GPCR nanodisc panel addresses the pressure scientists face to rapidly produce functional membrane proteins,” added Dr Michael Chen, CEO and Co-Founder of Nuclera. 

“Integrated with eProtein Discovery, this capability equips researchers with a powerful approach to increase success rates in expressing active GPCRs.” 

The post Nuclera launches GPCR-focused nanodisc panel  appeared first on Drug Discovery World (DDW).